Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | IARS1 | P41252 | 1/20 | 0.47 |
| ▸ | MARS1 | P56192 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660015 | 0.93 | MIF (0.51) | MIFUSP2MAPTHSD17B10ALDH1A1 | |
| SCHEMBL5689279 | 0.90 | TUBB4A (0.49) | MIFUSP2IARS1MARS1MAPT | |
| SCHEMBL12651372 | 0.86 | ALDH1A1 (0.46) | MIFUSP2MAOBMAPTHSD17B10 | |
| SCHEMBL13362374 | 0.86 | USP2 (0.53) | MIFUSP2MAPTHSD17B10ALDH1A1 | |
| SCHEMBL13644528 | 0.86 | USP2 (0.53) | MIFUSP2MAPTHSD17B10ALDH1A1 | |
| SCHEMBL3348174 | 0.83 | PTPN1 (0.53) | USP2HSD17B10ALDH1A1LMNAPTPN1 | |
| SCHEMBL5686355 | 0.83 | TUBB4A (0.52) | MIFUSP2MAPTHSD17B10ALDH1A1 | |
| SCHEMBL12607606 | 0.83 | MIF (0.54) | MIFMAOAMAOBIARS1MARS1 | |
| SCHEMBL13644516 | 0.82 | ALDH1A1 (0.56) | USP2MAOBMAPTALDH1A1PTPN1 | |
| SCHEMBL13644519 | 0.80 | PTPN1 (0.62) | USP2MAPTHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271648-B1 | ISOXAZOLINE LINKED PYRROLO [2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND THE PROCESS FOR PREPARATTION THEREOF | COUNCIL SCIENT IND RES (IN) | 2013-02-13 | — | — | EP | disclosed |
| EP-2271648-B1 | ISOXAZOLINE LINKED PYRROLO [2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND THE PROCESS FOR PREPARATTION THEREOF | COUNCIL SCIENT IND RES (IN) | 2013-02-13 | — | — | EP | disclosed |
| US-8372831-B2 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-02-12 | — | — | US | disclosed |
| US-8372831-B2 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-02-12 | — | — | US | disclosed |
| US-20110118237-A1 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-05-19 | — | — | US | disclosed |
| US-20110118237-A1 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-05-19 | — | — | US | disclosed |
| EP-2271648-A1 | ISOXAZOLINE LINKED PYRROLO [2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND THE PROCESS FOR PREPARATTION THEREOF | Council of Scientific & Industrial Research (IN) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009118748-A1 | ISOXAZOLINE LINKED PYRROLO[2,1-C[1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND THE PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118748-A1 | ISOXAZOLINE LINKED PYRROLO[2,1-C[1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND THE PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118237-A1 | Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof | GABRA5, GABRA1, CYP3A7 | MIF 3861/4885USP2 4016/4885MAOA 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.